Buprenorphine
- Generic Name
- Buprenorphine
- Brand Names
- Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41NO4
- CAS Number
- 52485-79-7
- Unique Ingredient Identifier
- 40D3SCR4GZ
- Background
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
- Indication
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
- Associated Conditions
- Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
- Associated Therapies
- -
Buprenorphine and Integrated HIV Care Evaluation
- Conditions
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2007-03-27
- Lead Sponsor
- The New York Academy of Medicine
- Target Recruit Count
- 1350
- Registration Number
- NCT00124358
- Locations
- 🇺🇸
The Miriam Hospital, Providence, Rhode Island, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Yale University School of Medicine AIDS Program, New Haven, Connecticut, United States
Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1
- Conditions
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 516
- Registration Number
- NCT00078117
- Locations
- 🇺🇸
Hartford Dispensary, Hartford, Connecticut, United States
🇺🇸Connecticut Counseling Centers, Waterbury, Connecticut, United States
🇺🇸LI Jewish Health System, Glen Oaks, New York, United States
Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Yale University
- Registration Number
- NCT00023283
- Locations
- 🇺🇸
APT Residential Services Division, New Haven, Connecticut, United States
Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2
- Conditions
- First Posted Date
- 2001-04-18
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00015041
- Locations
- 🇺🇸
Cincinnati MDRU, Cincinnati, Ohio, United States
Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice
- Conditions
- First Posted Date
- 2001-01-01
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 600
- Registration Number
- NCT00007527
- Locations
- 🇺🇸
Paul Casadonte, M.D. VAMC New York, New York, New York, United States
🇺🇸Andrew Saxon, M.D.-Addictions Treatment (116ATC), Seattle, Washington, United States
Treatment Efficacy for Drug Abuse and AIDS Prevention - 2
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000211
- Locations
- 🇺🇸
McLean Hospital, Dept. of Psychiatry, Belmont, Massachusetts, United States
Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 12
- Registration Number
- NCT00000299
- Locations
- 🇺🇸
Friends Research Institute, Los Angeles, California, United States
Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- University of Vermont
- Registration Number
- NCT00000240
- Locations
- 🇺🇸
Treatment Research Center, Burlington, Vermont, United States
Buprenorphine Maintenance for Opioid Addicts - 2
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Yale University
- Registration Number
- NCT00000203
- Locations
- 🇺🇸
VA Connecticut Healthcare System, New Haven, Connecticut, United States
Buprenorphine Maintenance for Opioid Addicts - 1
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Yale University
- Registration Number
- NCT00000202
- Locations
- 🇺🇸
VA Connecticut Healthcare System, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.